Krystal Biotech, Inc. KRYS
Set alert
As of Nov 3, 2:37 PM ET
- YTD
- +22.29%
- 1 year
- +52.38%
- Open
- 293.49
- Prev close
- 295.90
- Mkt cap
- 8.93B
- Vol
- 283.34K
- Avg vol
- 272.85K
- EPS
- 7.36
- P/E
- 40.96
- Div yield
- 0.00%
More statistics
- Low
- 293.26
- High
- 305.43
- Forward P/E
- 33.03
- Beta
- 0.65
- Short ratio
- 9.85
- Inst. own
- 104.39%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 16, 2027
- 50-d avg
- 337.46
- 200-d avg
- 308.53
- 1y target
- 395.44
1m chart
Built from the cached one-day intraday bars.
Signals (94)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Nov 3, 2:07 PM | 31 minutes ago |
| SMA: Bullish | Nov 3, 2:02 PM | 36 minutes ago |
| SMA: Bullish | Nov 3, 2:02 PM | 36 minutes ago |
| MACD: Buy Signal | Nov 3, 1:51 PM | 47 minutes ago |
| SMA: Bullish | Nov 3, 1:48 PM | 50 minutes ago |
| RSI: Oversold | Nov 3, 1:42 PM | 56 minutes ago |
| RSI: Oversold | Nov 3, 1:38 PM | 1 hour ago |
| SMA: Bearish | Nov 3, 1:32 PM | 1 hour ago |
| SMA: Bearish | Nov 3, 1:31 PM | 1 hour ago |
| SMA: Bullish | Nov 3, 1:30 PM | 1 hour ago |
| SMA: Bullish | Nov 3, 1:30 PM | 1 hour ago |
| SMA: Bearish | Nov 3, 1:27 PM | 1 hour ago |
| SMA: Bearish | Nov 3, 1:26 PM | 1 hour ago |
| SMA: Bullish | Nov 3, 1:22 PM | 1 hour ago |
| MACD: Sell Signal | Nov 3, 1:21 PM | 1 hour ago |
| SMA: Bearish | Nov 3, 1:20 PM | 1 hour ago |
| RSI: Overbought | Nov 3, 1:17 PM | 1 hour ago |
| RSI: Overbought | Nov 3, 1:04 PM | 1 hour ago |
| SMA: Bullish | Nov 3, 12:58 PM | 1 hour ago |
| SMA: Bearish | Nov 3, 12:57 PM | 1 hour ago |
Newest 20 of 94.
Key statistics
- Market cap
- 8.76B
- Enterprise value
- 9.00B
- Trailing P/E
- 37.08
- Forward P/E
- 33.03
- PEG ratio
- 0.00
- Price / sales
- 19.88
- Price / book
- 6.44
- EPS (TTM)
- 7.98
- Beta
- 0.65
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 54.82%
- Revenue (TTM)
- 440.48M
- Revenue growth
- 24.10%
- Free cash flow
- 151.74M
- Total cash
- 845.63M
- Total debt
- 8.85M
- Return on equity
- 20.12%
- Shares outstanding
- 29.60M
- Short % of float
- 16.24%
- 50-day average
- 337.46
- 200-day average
- 308.53
Analyst view
Consensus: strong buy
- Target (low)
- 284.00
- Target (mean)
- 395.44
- Target (high)
- 474.00
- Strong buy1
- Buy10
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 16, 2027
Expected Feb 16, 2027. Consensus EPS estimate 1.92.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 16, 2027 | Dec 30, 2026 | 1.91 | — | — | — |
| Nov 2, 2026 | Sep 30, 2026 | 1.79 | 2.05 | +0.26 | +14.53% |
| Aug 3, 2026 | Jun 30, 2026 | 1.70 | 1.79 | +0.09 | +5.29% |
| May 4, 2026 | Mar 31, 2026 | 1.45 | 1.83 | +0.38 | +26.21% |
| Feb 17, 2026 | Dec 31, 2025 | 1.62 | 1.70 | +0.08 | +4.94% |
| Nov 3, 2025 | Sep 30, 2025 | 1.12 | 2.66 | +1.54 | +137.50% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 15, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 21, 2026 | B of A Securities | main | Buy | Buy |
| Aug 14, 2026 | RBC Capital | init | — | Outperform |
| Aug 4, 2026 | Citigroup | main | Buy | Buy |
| Jul 14, 2026 | B of A Securities | main | Buy | Buy |
| Jun 18, 2026 | TD Cowen | main | Buy | Buy |
About Krystal Biotech, Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- krystalbio.com
News
- Citigroup Maintains Buy on Krystal Biotech, Lowers Price Target to $412
- TD Cowen Maintains Buy on Krystal Biotech, Lowers Price Target to $380
- RBC Capital Maintains Outperform on Krystal Biotech, Lowers Price Target to $375
- Krystal Biotech Analyst Says Stock Weakness 'Overblown'
- Krystal Biotech Analyst Says Stock Weakness 'Overblown'
- Krystal Biotech, Inc. (KRYS) Q3 2026 Earnings Call Transcript
- Krystal Biotech, Inc. (KRYS) Surpasses Q3 Earnings and Revenue Estimates
- Nasdaq Rallies as Tech Stocks Recover From Friday's Selloff
- Krystal Biotech Q3 Earnings Call Highlights
- Krystal Biotech Q3 2026 Earnings Call Transcript
Your note
Sign in to keep a note on KRYS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| JANNEY DANIEL SPENCER | Director | Sale | Feb 26, 2026 | 0 |
| KRISHNAN KRISH S | Chief Executive Officer | Sale | Sep 3, 2026 | 1,565,250 |
| KRISHNAN SUMA M | Officer, Director and Beneficial Owner | Sale | Sep 3, 2026 | 1,493,160 |
| ROMANO KATHRYN | Officer | Sale | Mar 1, 2026 | 22,366 |
| ROSSI DINO A | Director | Stock Gift | Aug 13, 2026 | 50,000 |
| THOMAS JOHN CHARLES MICHAEL | General Counsel | Sale | Jun 24, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.93% | 4,418,197 | 1.31B | Jun 29, 2026 |
| Blackrock Inc. | 14.13% | 4,181,432 | 1.24B | Jun 29, 2026 |
| Avoro Capital Advisors LLC | 9.76% | 2,888,888 | 854.82M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.32% | 1,574,905 | 466.01M | Jun 29, 2026 |
| State Street Corporation | 4.56% | 1,351,158 | 399.81M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.19% | 1,240,567 | 367.08M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 6.09% | 1,802,622 | 533.40M | Aug 30, 2026 |
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.21% | 948,897 | 280.78M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.01% | 889,548 | 263.22M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 2.76% | 816,132 | 241.49M | Aug 30, 2026 |
| SmallCap World Fund Inc | 2.54% | 752,244 | 222.59M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.28% | 675,066 | 199.75M | Sep 29, 2026 |